查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1813840

美國過敏和自體免疫疾病診斷市場規模、佔有率和趨勢分析（按產品/服務、測試類型、診斷類型、最終用途和細分市場），2025 年至 2033 年

U.S. Allergy And Autoimmune Disease Diagnostics Market Size, Share & Trends Analysis Report By Product & Services (Allergy Diagnostics, Autoimmune Disease), By Test Type, By Diagnostics Type, By End-use, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

市場規模與趨勢：

美國過敏和自體免疫疾病診斷市場預計在 2024 年價值 40.3 億美元，預計到 2033 年將達到 84 億美元，2025 年至 2033 年的複合年成長率為 8.67%。

這一市場的主要促進因素包括過敏和自體免疫疾病的盛行率上升、患者意識的增強以及專業診斷檢測的普及。過敏診斷廣泛應用於識別特異性IgE介導的反應，而自體免疫疾病診斷則支持類風濕性關節炎、全身性紅斑性狼瘡和多發性硬化症等複雜疾病的早期發現和鑑別診斷。

此外，隨著過敏和自體免疫疾病診斷檢測量的不斷增加，樣本處理、檢測通量和數據報告也需要顯著改善。這些改進有助於提高實驗室營運效率，並擴大專業檢測的覆蓋範圍。越來越多的實驗室採用自動化和整合平台來管理日益成長的需求、簡化工作流程，並維持日益複雜的檢測的準確性。

數位化報告系統及其與電子健康記錄的連結進一步改善了診斷團隊和臨床醫生之間的協作。這些工具縮短了周轉時間，並支持在慢性過敏和自體免疫疾病的管理中及時做出臨床決策。

美國市場正經歷由研發驅動的持續創新，並轉向更具針對性的診斷解決方案。 2025年4月，貝克曼庫爾特生命科學公司推出了新一代嗜鹼性粒細胞活化檢測 (BAT)，以支持過敏研究。雖然該檢測專為研究用途而設計，但它反映出人們越來越重視功能性檢測，以便更深入地了解免疫細胞行為和過敏誘因。

與之相關的一項進展是，Well Theory 於 2023 年 10 月宣布推出一項企業解決方案，旨在透過雇主和付款人網路解決自體免疫的護理問題。該平台專注於系統化、基於生活方式的自體免疫疾病管理，凸顯了將診斷與持續患者支持相結合的市場趨勢。此類努力反映出，診斷與照護服務模式日益融合，旨在改善慢性免疫疾病患者的長期預後。

美國市場正朝著更專業、數據主導的模式發展，將診斷與個人化照護緊密結合。隨著檢測技術日益成熟和普及，預計市場將受益於臨床整合的增強、病人參與的提升，以及在傳統醫療機構和新興醫療平台的廣泛應用。

目錄

第1章調查方法與範圍

第2章執行摘要

第 3 章美國過敏和自體免疫疾病診斷市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 美國過敏與自體免疫疾病診斷市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章美國過敏和自體免疫疾病診斷市場：產品和服務估計和趨勢分析

  • 2024 年和 2033 年產品和服務市場佔有率
  • 細分儀表板
  • 美國過敏和自體免疫疾病診斷市場：產品和服務展望
  • 過敏診斷
    • 裝置
    • 耗材
    • 服務
  • 自體免疫疾病的診斷
    • 裝置
    • 耗材
    • 服務

第5章美國過敏和自體免疫疾病診斷市場：測試類型估計和趨勢分析

  • 2024 年和 2033 年測試類型市場佔有率
  • 細分儀表板
  • 美國過敏和自體免疫疾病診斷市場：按測試類型分類的展望
  • 過敏診斷
    • 體內測試
  • 自體免疫疾病的診斷
    • 抗核抗體檢測
    • 自體抗體檢測
    • C反應蛋白（CRP）
    • 全血球計數（CBC）
    • 尿液檢查
    • 其他

第6章美國過敏和自體免疫疾病診斷市場：診斷類型估計和趨勢分析

  • 2024 年和 2033 年診斷類型市場佔有率
  • 細分儀表板
  • 美國過敏與自體免疫疾病診斷市場：按診斷類型分類的展望
  • 過敏診斷
    • 食物
    • 吸入
    • 藥品
    • 其他過敏原
  • 自體免疫疾病
    • 系統性自體免疫疾病的診斷
    • 局部自體免疫疾病診斷

第7章美國過敏和自體免疫疾病診斷市場：最終用途估計和趨勢分析

  • 2024年和2033年的最終用途市場佔有率
  • 細分儀表板
  • 過敏和自體免疫疾病診斷市場：最終用途差異分析
  • 過敏診斷
    • 醫院和診所
    • 診斷實驗室
    • 研究機構
    • 其他
  • 自體免疫診斷
    • 醫院和診所
    • 診斷實驗室
    • 研究機構
    • 其他

第8章 競爭態勢

  • 公司分類
  • 戰略地圖
    • 推出新產品和服務
    • 夥伴關係
    • 獲得
    • 合作
    • 資金籌措
  • 2024年主要企業市佔率分析
  • 公司熱圖分析
  • 公司簡介
    • Thermo Fisher Scientific, Inc.
    • HYCOR Biomedical
    • EUROIMMUN Medizinische Labordiagnostika AG（PerkinElmer）
    • Omega Diagnostics GROUP PLC
    • Lincoln Diagnostics, Inc.
    • AESKU.GROUP GmbH
    • Minaris Medical America, Inc.
    • HOB Biotech Group Corp., Ltd.
    • DASIT Group SPA
    • R-Biopharm AG
    • BIOMERIEUX
    • Siemens Healthcare GmbH
    • Hoffmann-La Roche Ltd
    • Abbott
    • Beckman Coulter, Inc.
    • Danaher Corporation
    • Quest Diagnostics
    • Nova Diagnostics Pte Ltd.
Product Code: GVR-4-68040-695-1

Market Size & Trends:

The U.S. allergy and autoimmune disease diagnostics market size was estimated at USD 4.03 billion in 2024 and is projected to reach USD 8.40 billion by 2033, growing at a CAGR of 8.67% from 2025 to 2033. The market is primarily driven by the rising incidence of allergic and autoimmune disorders, increasing patient awareness, and improved access to specialized diagnostic testing. Allergy diagnostics are widely used to identify specific IgE-mediated reactions, while autoimmune disease diagnostics support early detection and differentiation of complex conditions such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.

In addition, the growing volume of diagnostic testing for allergy and autoimmune conditions has prompted significant improvements in sample handling, assay throughput, and data reporting. These enhancements support more efficient laboratory operations and expand access to specialized tests. Laboratories are increasingly adopting automation and integrated platforms to manage rising demand, streamline workflows, and maintain accuracy in high-complexity testing.

Digitized reporting systems and connectivity with electronic health records further improve coordination between diagnostic teams and clinicians. These tools reduce turnaround times and support timely clinical decision-making in managing chronic allergic and autoimmune conditions.

The U.S. market is experiencing continuous innovation, driven by research-focused developments and a shift toward more targeted diagnostic solutions. In April 2025, Beckman Coulter Life Sciences introduced its Next-Generation Basophil Activation Test (BAT) to support allergy research. Although designed for research use only, the test reflects a growing emphasis on functional assays that offer deeper insights into immune cell behavior and allergic triggers.

In a related development, WellTheory launched an enterprise solution in October 2023 to address autoimmune care through employer and payer networks. This platform focuses on structured, lifestyle-based management of autoimmune symptoms, underscoring a broader market trend toward integrating diagnostics with ongoing patient support. These efforts reflect how diagnostics are increasingly paired with care delivery models to improve long-term outcomes for individuals with chronic immune conditions.

The U.S. market is evolving toward more specialized, data-driven approaches that align diagnostics with personalized care. As testing technologies become more sophisticated and accessible, the market is expected to benefit from stronger clinical integration, improved patient engagement, and broader adoption across traditional healthcare settings and emerging care platforms.

U.S. Allergy And Autoimmune Disease Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. allergy and autoimmune disease diagnostics market report based on products & services, diagnostic type, test type, and end use:

  • Products & Services Outlook (Revenue in USD Million, 2021 - 2033)
  • Allergy Diagnostics
    • Instruments
    • Consumables
    • Services
  • Autoimmune Disease Diagnostics
    • Instruments
    • Consumables
    • Services
  • Test Type Outlook (Revenue in USD Million, 2021 - 2033)
  • Allergy Diagnostics
    • In vivo Test
    • Skin Prick Test
    • Intradermal Test
    • Patch Test
    • In vitro Test
  • Autoimmune Disease Diagnostics
    • Antinuclear Antibody Tests
    • Autoantibody Tests
    • C-reactive Protein (CRP)
    • Complete Blood Count (CBC)
    • Urinalysis
    • Others
  • Diagnostics Type Outlook (Revenue in USD Million, 2021 - 2033)
  • Allergy Diagnostics
    • Food
    • Dairy Products
    • Poultry Product
    • Tree Nuts
    • Peanuts
    • Shellfish
    • Wheat
    • Soys
    • Other Food Allergens
    • Inhaled
    • Drug
    • Other Allergens
  • Autoimmune Disease Diagnostics
    • Systemic Autoimmune Disease Diagnostics
    • Rheumatoid Arthritis
    • Ankylosing Spondylitis
    • Systemic Lupus Erythematosus (SLE)
    • Others
    • Localized Autoimmune Disease Diagnostics
    • Multiple Sclerosis
    • Type 1 Diabetes
    • Hashimoto's Thyroiditis
    • Idiopathic Thrombocytopenic Purpura
    • Others
  • End Use Outlook (Revenue in USD Million, 2021 - 2033)
  • Allergy Diagnostics
    • Hospitals & Clinics
    • Diagnostics Laboratories
    • Research Institutions
    • Others
  • Autoimmune Disease
    • Hospitals & Clinics
    • Diagnostics Laboratories
    • Research Institutions
    • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Products and Services
    • 1.2.2. Test Type
    • 1.2.3. Diagnostic Type
    • 1.2.4. End Use
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in U.S.
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Products and Services and Test type Snapshot
    • 2.2.2. Diagnostics Type Snapshot
    • 2.2.3. End Use Snapshot
  • 2.3. Competitive Insights

Chapter 3. U.S. Allergy and Autoimmune Disease Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising Prevalence of Immune-Related Disorders
      • 3.2.1.2. Shift Toward Early and Personalized Diagnosis
      • 3.2.1.3. Expansion of Decentralized and Home-Based Testing
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High Cost of Advanced Diagnostic Technologies
      • 3.2.2.2. Underdiagnosis and Limited Awareness in Emerging Markets
      • 3.2.2.3. Regulatory and Reimbursement Barriers
  • 3.3. U.S. Allergy And Autoimmune Disease Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Allergy And Autoimmune Disease Diagnostics Market: Products and Services Estimates & Trend Analysis

  • 4.1. Products and Services Market Share, 2024 & 2033
  • 4.2. Segment Dashboard
  • 4.3. U.S. Allergy And Autoimmune Disease Diagnostics Market, by Products and Services Outlook
  • 4.4. Allergy Diagnostics
    • 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Instruments
      • 4.4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Consumables
      • 4.4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.4. Services
      • 4.4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Autoimmune Disease Diagnostics
    • 4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.2. Instruments
      • 4.5.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.3. Consumables
      • 4.5.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.4. Services
      • 4.5.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Allergy And Autoimmune Disease Diagnostics Market: Test Type Estimates & Trend Analysis

  • 5.1. Test Type Market Share, 2024 & 2033
  • 5.2. Segment Dashboard
  • 5.3. U.S. Allergy And Autoimmune Disease Diagnostics Market by Test Type Outlook
  • 5.4. Allergy Diagnostics
    • 5.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.2. In vivo Test
      • 5.4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.4.2.2. Skin Prick Test
        • 5.4.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.4.2.3. Intradermal Test
        • 5.4.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.4.2.4. Patch Test
        • 5.4.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.4.2.5. In vitro Test
        • 5.4.2.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Autoimmune Disease Diagnostics
    • 5.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.2. Antinuclear Antibody Tests
      • 5.5.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.3. Autoantibody Tests
      • 5.5.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.4. C-reactive Protein (CRP)
      • 5.5.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.5. Complete Blood Count (CBC)
      • 5.5.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.6. Urinalysis
      • 5.5.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.7. Others
      • 5.5.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Allergy And Autoimmune Disease Diagnostics Market: Diagnostics Type Estimates & Trend Analysis

  • 6.1. Diagnostics Type Market Share, 2024 & 2033
  • 6.2. Segment Dashboard
  • 6.3. U.S. Allergy And Autoimmune Disease Diagnostics Market by Diagnostics Type Outlook
  • 6.4. Allergy Diagnostics
    • 6.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.2. Food
      • 6.4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.4.2.2. Dairy Products
        • 6.4.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.4.2.3. Poultry Product
        • 6.4.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.4.2.4. Tree Nuts
        • 6.4.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.4.2.5. Peanuts
        • 6.4.2.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.4.2.6. Shellfish
        • 6.4.2.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.4.2.7. Wheat
        • 6.4.2.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.4.2.8. Soys
        • 6.4.2.8.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.4.2.9. Other Food Allergens
        • 6.4.2.9.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Inhale
      • 6.4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Drug
      • 6.4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.5. Other allergens
      • 6.4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Autoimmune Disease
    • 6.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. Systemic Autoimmune Disease Diagnostics
      • 6.5.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.5.2.2. Rheumatoid Arthritis
        • 6.5.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.5.2.3. Ankylosing Spondylitis
        • 6.5.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.5.2.4. Systemic Lupus Erythematosus (SLE)
        • 6.5.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.5.2.5. Others
        • 6.5.2.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Localized Autoimmune Disease Diagnostics
      • 6.5.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.5.3.2. Multiple Sclerosis
        • 6.5.3.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.5.3.3. Type 1 Diabetes
        • 6.5.3.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.5.3.4. Hashimoto's Thyroiditis
        • 6.5.3.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.5.3.5. Idiopathic Thrombocytopenic Purpura
        • 6.5.3.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.5.3.6. Others
        • 6.5.3.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Allergy And Autoimmune Disease Diagnostics Market: End Use Estimates & Trend Analysis

  • 7.1. End Use Market Share, 2024 & 2033
  • 7.2. Segment Dashboard
  • 7.3. Allergy and Autoimmune Disease Diagnostics Market: End Use Movement Analysis
  • 7.4. Allergy Diagnostics
    • 7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. Hospitals & Clinics
      • 7.4.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Diagnostics Laboratories
      • 7.4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Research Institutions
      • 7.4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.5. Others
      • 7.4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Autoimmune Diagnostics
    • 7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. Hospitals & Clinics
      • 7.5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Diagnostics Laboratories
      • 7.5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. Research Institutions
      • 7.5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Others
      • 7.5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. New Products and Services Launch
    • 8.2.2. Partnerships
    • 8.2.3. Acquisition
    • 8.2.4. Collaboration
    • 8.2.5. Funding
  • 8.3. Key Company Market Share Analysis, 2024
  • 8.4. Company Heat Map Analysis
  • 8.5. Company Profiles
    • 8.5.1. Thermo Fisher Scientific, Inc.
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Products and Services Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. HYCOR Biomedical
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Products and Services Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. EUROIMMUN Medizinische Labordiagnostika AG (PerkinElmer)
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Products and Services Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Omega Diagnostics GROUP PLC
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Products and Services Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Lincoln Diagnostics, Inc.
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Products and Services Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. AESKU.GROUP GmbH
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Products and Services Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Minaris Medical America, Inc.
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Products and Services Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. HOB Biotech Group Corp., Ltd.
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Products and Services Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. DASIT Group SPA
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Products and Services Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. R-Biopharm AG
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Products and Services Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. BIOMERIEUX
      • 8.5.11.1. Company Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Products and Services Benchmarking
      • 8.5.11.4. Strategic Initiatives
    • 8.5.12. Siemens Healthcare GmbH
      • 8.5.12.1. Company Overview
      • 8.5.12.2. Financial Performance
      • 8.5.12.3. Products and Services Benchmarking
      • 8.5.12.4. Strategic Initiatives
    • 8.5.13. Hoffmann-La Roche Ltd
      • 8.5.13.1. Company Overview
      • 8.5.13.2. Financial Performance
      • 8.5.13.3. Products and Services Benchmarking
      • 8.5.13.4. Strategic Initiatives
    • 8.5.14. Abbott
      • 8.5.14.1. Company Overview
      • 8.5.14.2. Financial Performance
      • 8.5.14.3. Products and Services Benchmarking
      • 8.5.14.4. Strategic Initiatives
    • 8.5.15. Beckman Coulter, Inc.
      • 8.5.15.1. Company Overview
      • 8.5.15.2. Financial Performance
      • 8.5.15.3. Products and Services Benchmarking
      • 8.5.15.4. Strategic Initiatives
    • 8.5.16. Danaher Corporation
      • 8.5.16.1. Company Overview
      • 8.5.16.2. Financial Performance
      • 8.5.16.3. Products and Services Benchmarking
      • 8.5.16.4. Strategic Initiatives
    • 8.5.17. Quest Diagnostics
      • 8.5.17.1. Company Overview
      • 8.5.17.2. Financial Performance
      • 8.5.17.3. Products and Services Benchmarking
      • 8.5.17.4. Strategic Initiatives
    • 8.5.18. Nova Diagnostics Pte Ltd.
      • 8.5.18.1. Company Overview
      • 8.5.18.2. Financial Performance
      • 8.5.18.3. Products and Services Benchmarking
      • 8.5.18.4. Strategic Initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. Allergy and Autoimmune Disease Diagnostics Market, by products and services, 2021 - 2033 (USD Million)
  • Table 3 U.S. Allergy and Autoimmune Disease Diagnostics Market, by test type, 2021 - 2033 (USD Million)
  • Table 4 U.S. Allergy and Autoimmune Disease Diagnostics Market, by diagnostics type, 2021 - 2033 (USD Million)
  • Table 5 U.S. Allergy and Autoimmune Disease Diagnostics Market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in U.S.
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. allergy and autoimmune disease diagnostics market: Market outlook
  • Fig. 10 U.S. allergy and autoimmune disease diagnostics competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. allergy and autoimmune disease diagnostics market driver impact
  • Fig. 16 U.S. allergy and autoimmune disease diagnostics market restraint impact
  • Fig. 17 U.S. allergy and autoimmune disease diagnostics market strategic initiatives analysis
  • Fig. 18 U.S. allergy and autoimmune disease diagnostics market: Products and services movement analysis
  • Fig. 19 U.S. allergy and autoimmune disease diagnostics market: Products and services outlook and key takeaways
  • Fig. 20 Allergy diagnostics market estimates, 2021 - 2033 (USD Million)
  • Fig. 21 Instruments market estimates, 2021 - 2033 (USD Million)
  • Fig. 22 Consumables market estimates, 2021 - 2033 (USD Million)
  • Fig. 23 Services market estimates, 2021 - 2033 (USD Million)
  • Fig. 24 Autoimmune disease diagnostics market estimates, 2021 - 2033 (USD Million)
  • Fig. 25 Instruments market estimates, 2021 - 2033 (USD Million)
  • Fig. 26 Consumables market estimates, 2021 - 2033 (USD Million)
  • Fig. 27 Services market estimates, 2021 - 2033 (USD Million)
  • Fig. 28 U.S. allergy and autoimmune disease diagnostics market: Test type movement analysis
  • Fig. 29 U.S. allergy and autoimmune disease diagnostics market: Test type outlook and key takeaways
  • Fig. 30 Allergy diagnostics market estimates, 2021 - 2033 (USD Million)
  • Fig. 31 In vivo test market estimates, 2021 - 2033 (USD Million)
  • Fig. 32 Skin prick test market estimates, 2021 - 2033 (USD Million)
  • Fig. 33 Intradermal test market estimates, 2021 - 2033 (USD Million)
  • Fig. 34 Patch test market estimates, 2021 - 2033 (USD Million)
  • Fig. 35 In vitro test market estimates, 2021 - 2033 (USD Million)
  • Fig. 36 Autoimmune disease diagnostics test market estimates, 2021 - 2033 (USD Million)
  • Fig. 37 Antinuclear antibody tests market estimates, 2021 - 2033 (USD Million)
  • Fig. 38 Autoantibody tests estimates, 2021 - 2033 (USD Million)
  • Fig. 39 C-reactive Protein (CRP) market estimates, 2021 - 2033 (USD Million)
  • Fig. 40 Complete Blood Count (CBC) market estimates, 2021 - 2033 (USD Million)
  • Fig. 41 Urinalysis market estimates, 2021 - 2033 (USD Million)
  • Fig. 42 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 43 U.S. allergy and autoimmune disease diagnostics market: Diagnostics type movement analysis
  • Fig. 44 U.S. allergy and autoimmune disease diagnostics market: Diagnostics type outlook and key takeaways
  • Fig. 45 Allergy diagnostics market estimates, 2021 - 2033 (USD Million)
  • Fig. 46 Food market estimates, 2021 - 2033 (USD Million)
  • Fig. 47 Dairy products market estimates, 2021 - 2033 (USD Million)
  • Fig. 48 Poultry product market estimates, 2021 - 2033 (USD Million)
  • Fig. 49 Tree nuts market estimates, 2021 - 2033 (USD Million)
  • Fig. 50 Peanuts market estimates, 2021 - 2033 (USD Million)
  • Fig. 51 Shellfish market estimates, 2021 - 2033 (USD Million)
  • Fig. 52 Wheat market estimates, 2021 - 2033 (USD Million)
  • Fig. 53 Soys market estimates, 2021 - 2033 (USD Million)
  • Fig. 54 Other food allergens market estimates, 2021 - 2033 (USD Million)
  • Fig. 55 Inhaled market estimates, 2021 - 2033 (USD Million)
  • Fig. 56 Drug market estimates, 2021 - 2033 (USD Million)
  • Fig. 57 Other allergens market estimates, 2021 - 2033 (USD Million)
  • Fig. 58 Autoimmune disease diagnostics market estimates, 2021 - 2033 (USD Million)
  • Fig. 59 Systemic autoimmune disease diagnostics market estimates, 2021 - 2033 (USD Million)
  • Fig. 60 Rheumatoid arthritis market estimates, 2021 - 2033 (USD Million)
  • Fig. 61 Ankylosing spondylitis market estimates, 2021 - 2033 (USD Million)
  • Fig. 62 Systemic Lupus Erythematosus (SLE) market estimates, 2021 - 2033 (USD Million)
  • Fig. 63 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 64 Localized autoimmune disease diagnostics market estimates, 2021 - 2033 (USD Million)
  • Fig. 65 Multiple sclerosis market estimates, 2021 - 2033 (USD Million)
  • Fig. 66 Type 1 diabetes market estimates, 2021 - 2033 (USD Million)
  • Fig. 67 Hashimoto's thyroiditis market estimates, 2021 - 2033 (USD Million)
  • Fig. 68 Idiopathic thrombocytopenic purpura market estimates, 2021 - 2033 (USD Million)
  • Fig. 69 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 70 U.S. allergy and autoimmune disease diagnostics market: End use movement analysis
  • Fig. 71 U.S. allergy and autoimmune disease diagnostics market: End use outlook and key takeaways
  • Fig. 72 Allergy Diagnostics market estimates, 2021 - 2033 (USD Million)
  • Fig. 73 Hospitals & clinics market estimates, 2021 - 2033 (USD Million)
  • Fig. 74 Diagnostics laboratories market estimates, 2021 - 2033 (USD Million)
  • Fig. 75 Research institutions market estimates, 2021 - 2033 (USD Million)
  • Fig. 76 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 77 Autoimmune diagnostics market estimates, 2021 - 2033 (USD Million)
  • Fig. 78 Hospitals & clinics market estimates, 2021 - 2033 (USD Million)
  • Fig. 79 Diagnostics laboratories market estimates, 2021 - 2033 (USD Million)
  • Fig. 80 Research institutions market estimates, 2021 - 2033 (USD Million)
  • Fig. 81 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 82 U.S. allergy and autoimmune disease diagnostics market share and leading players
  • Fig. 83 U.S. market share and leading players
  • Fig. 84 U.S. SWOT
  • Fig. 85 U.S. market estimates and forecasts, 2021 - 2033
  • Fig. 86 Market share of key market players- U.S. allergy and autoimmune disease diagnostics market